welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

Since the 1970s, the FDA has helped to facilitate access to promising investigational medical products for patients with serious or immediately life-threatening diseases who are unable to access products through clinical trials. As a cancer survivor, I understand, on a very personal level, that patients who are fighting serious or life-threatening diseases want the flexibility to try new therapeutic approaches, including investigational medical products. This is especially relevant when there’s no other FDA-approved treatment option available to a patient.

Statement From FDA Commissioner Scott Gottlieb, M.D., On New Efforts To Strengthen FDA’s Expanded Access Program